aTyr Pharma

aTyr Pharma(ATYR)

SAN DIEGO, CA
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Therapeutic Proteins

aTyr Pharma is a life sciences company focused on Therapeutic Proteins.

RespiratoryInfectious Diseases
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Lif
Facioscapulohumeral Muscular Dystrophy
N/A
Clinical Trials (1)
NCT01437345A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD
N/A
Phase 1/2
Clinical Trials (1)
NCT02239224Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02603562Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
Phase 1/2
Efzofitimod 1.0 mg/kg or Placebo
Pulmonary Sarcoidosis
Phase 1/2
Clinical Trials (1)
NCT03824392Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02836418Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02531217Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02579239Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 1/2
efzofitimod 450 mg
Interstitial Lung Disease
Phase 2
Clinical Trials (1)
NCT05892614Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Phase 2
Phase 2
Clinical Trials (1)
NCT04412668Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
Phase 2
Efzofitimod 3 mg/kg
Pulmonary Sarcoidosis
Phase 3
Clinical Trials (1)
NCT05415137Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 10 clinical trials
SEC Filings: 2 available

Financials (FY2025)

Revenue
$353K97%
R&D Spend
$42M(11981%)1%
Net Income
-$50M
Cash
$23M
Source: SEC 10-K Filing